Question to the Department of Health and Social Care:

To ask the Secretary of State for Health and Social Care, whether he has had recent discussions with the National Institute for Health and Care Excellence on access to Fampridine for people with multiple sclerosis.

There have been no specific discussions. The National Institute for Health and Care Excellence (NICE) is the independent body responsible for developing evidence-based guidance for the National Health Service on whether medicines represent a clinical and cost-effective use of resources. NICE was unable to recommend fampridine in its clinical guideline on managing multiple sclerosis which was originally published in 2014 and updated in 2022.